To study the effects of the amlodipine and atorvastatin on the blood levels of endothelial vasoactive mediators in patients with metabolic syndrome (MS).Design and method:
In our study we included 60 patients with MS and mild arterial hypertension. Patients were randomized into three treatment groups: monotherapy with amlodipine, monotherapy with atorvastatin and a combination therapy with amlodipine and atorvastatin. Office blood pressure (BP), NO metabolite levels («Shimadzu», Japan), endothelin-1 (ET-1) («Biomedica Gruppe», Austria), thromboxane B2 (TxB2) and 6-keto-prostaglandin F1α (6-ketoPG F1.α) (Assay designs) were performed at baseline and after 24 weeks of the therapy. In the control group was had 20 healthy volunteers. Data were represented as median (Med) and 25%-75% interquartile range or mean and standard deviation. p-value < 0,05 was considered as statistically significantResults:
Monotherapy with amlodipine and combination therapy with amlodipine and atorvastatin were associated with the significant decreased office BP. Initially TxB2, 6-ketoPG F1α, ET-1 levels were significantly higher at patients with MS then in control group. Difference in NO metabolite level didn’t reach statistical significance. Monotherapy with amlodipine and atorvastatin or in a combination showed significant improvements in several studied parameters of endothelial vasoactive mediators. The results are shown in table 1.Conclusions:
Amlodipine and atorvastatin treatment was showed positive effects on the levels of vasoactive mediators thereby leading to the improvement of endothelial function in patients with MS.